SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
Instagram Outage Disrupts Thousands of U.S. Users 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Qantas to Sell Jetstar Japan Stake as It Refocuses on Core Australian Operations 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
NEW YORK, Aug. 07, 2017 -- Shepherd, Finkelman, Miller & Shah, LLP (“SFMS”) announces that a class action lawsuit has been filed in the United States District Court for the District of New Jersey (Civil Action No. 17-05011) against Ocular Therapeutix, Inc. (“Ocular” or the “Company”) (Nasdaq:OCUL) and certain of its officers and directors. The case seeks remedies under the Securities Exchange Act of 1934 and is brought on behalf of a class consisting of all persons or entities that acquired Ocular securities between May 5, 2017 and July 6, 2017, inclusive (the “Class Period”). If you would like to discuss this action or have any questions regarding this notice or your rights, please contact either Bruce Parke ([email protected]) or Jonathan Dilger ([email protected]); (866) 540-5505.
The Complaint alleges that, throughout the Class Period, Ocular made false and/or misleading statements and/or failed to disclose that: (1) the Company was experiencing issues concerning the manufacture of its lead product, Dextenza, including that more than half the lots the Company produced contained bad product; (2) the foregoing issues could jeopardize Dextenza’s prospects of approval by the FDA; and (3) as a result, defendants’ public statements were materially false and misleading at all relevant times.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN AN ATTORNEY. YOU MAY RETAIN COUNSEL OF YOUR CHOICE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS TIME. If you purchased or otherwise acquired Ocular securities during the Class Period, we encourage you to contact us with any questions prior to the September 5, 2017 lead plaintiff motion deadline.
SFMS is recognized as an accomplished firm in the areas of securities, corporate governance, antitrust and employee benefits litigation with offices in California, Connecticut, Florida, New Jersey, New York and Pennsylvania, as well as affiliate offices in London, England, and Milan, Italy. SFMS has recovered hundreds of millions of dollars on behalf of investors. For more information visit us at http://www.sfmslaw.com.
Contacts: Bruce Parke Jonathan Dilger Shepherd Finkelman Miller & Shah, LLP www.sfmslaw.com Telephone: (866) 540-5504 Email: [email protected] [email protected]
